Events

Events

Management
Board of Directors
Scientific Advisory Board

Repotrectinib
TPX-0022
TPX-0046
ALK Inhibitor

OUR SCIENCE

Our Approach
Addressing Resistance
Publications

CLINICAL TRIALS

TRIDENT-1
Compassionate Use

Press Releases
Publications

Mission and Values
Our Culture
Opportunities

Terms of Use | Copyright © 2019 Turning Point Therapeutics, Inc. | All Rights Reserved